MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors

BACKGROUND: Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) agents have only moderate antitumor activity in some advanced solid tumors (AST), including breast cancer (BC), prostate cancer (PC), cervical cancer (CC), and head and neck cancer (HNC). Combining anti-PD-L1 wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vicier, C., Isambert, N., Cropet, C., Hamimed, M., Osanno, L., Legrand, F., de La Motte Rouge, T., Ciccolini, J., Gonçalves, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808477/
https://www.ncbi.nlm.nih.gov/pubmed/36521418
http://dx.doi.org/10.1016/j.esmoop.2022.100646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808477/
https://www.ncbi.nlm.nih.gov/pubmed/36521418
http://dx.doi.org/10.1016/j.esmoop.2022.100646

Ejemplares similares